Loading clinical trials...
Loading clinical trials...
This was a multicenter, open-label safety study to determine the dose regimen of SYNT001 (ALXN1830) administered intravenously in participants with pemphigus (vulgaris or foliaceus).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alexion Pharmaceuticals, Inc.
NCT05954416 · Inherited Epidermolysis Bullosa, Ichthyosis, and more
NCT06696716 · Pemphigus, Steroid-resistant Pemphigus
NCT02753777 · Pemphigus Vulgaris, Pemphigus Foliaceus, and more
NCT07461103 · Pemphigus Vulgaris, Skin Erosion, and more
NCT06663943 · Pemphigus Disease, Pemphigus Vulgaris (PV)
Alexion Study Site
Chapel Hill, North Carolina
Alexion Study Site
Durham, North Carolina
Alexion Study Site
Philadelphia, Pennsylvania
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions